NCT05077800 2025-11-18
FOLFIRINOX + Elraglusib + Losartan In Pancreatic Cancer
Massachusetts General Hospital
Phase 2 Active not recruiting
Clinical Trials
12 trialsNCT06149689 2025-08-07
PTCA199-7
Fudan University
Phase 2 Recruiting
NCT05624918 2025-07-31
A Study of NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma
Big Ten Cancer Research Consortium
Phase 2 Recruiting
NCT04992507 2025-07-10
Impact of Total Intravenous Anesthesia Following Cancer Surgery, TIVACS Study
Ohio State University Comprehensive Cancer Center
Phase 2 Terminated
NCT06789679 2025-01-30
Albumin-Bound Paclitaxel and Gemcitabine With or Without S-1 as First-Line Treatment for Advanced Pancreatic Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
NCT04986930 2025-01-28
SABER
Asan Medical Center
Phase 2 Active not recruiting
NCT02427841 2023-09-06
Nab-paclitaxel and Gemcitabine Hydrochloride Followed by Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
OHSU Knight Cancer Institute
Phase 2 Completed
NCT02806687 2023-03-30
THERGAP-02
University Hospital, Toulouse
Phase 2 Completed
NCT02839343 2022-05-24
Combination Chemotherapy With or Without Hypofractionated Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Unknown
NCT03528785 2021-08-02
nITRo
Centro Ricerche Cliniche di Verona
Phase 2 Unknown
NCT02749136 2019-11-25
Neoadjuvant Modified FOLFIRINOX in Borderline Resectable Pancreatic Cancer
Asan Medical Center
Phase 2 Completed
NCT02736578 2019-06-25
Cetuximab-IRDye 800CW and Intraoperative Imaging in Finding Pancreatic Cancer in Patients Undergoing Surgery
Stanford University
Phase 2 Terminated